Here are the 10-K annual reports from BeyondSpring Inc. (BYSI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BYSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYSI filings page.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.